Literature DB >> 16645138

Persistent infarct hyperintensity on diffusion-weighted imaging late after stroke indicates heterogeneous, delayed, infarct evolution.

Carly S Rivers1, Joanna M Wardlaw, Paul A Armitage, Mark E Bastin, Trevor K Carpenter, Vera Cvoro, Peter J Hand, Martin S Dennis.   

Abstract

BACKGROUND AND
PURPOSE: Some infarcts have persistently hyperintense areas on diffusion-weighted MRI (DWI) even at 1 month after stroke, whereas others have become isointense to normal brain. We hypothesized that late DWI hyperintensity reflected different infarct evolution compared with areas that were isointense by 1 month.
METHODS: We recruited patients prospectively with ischemic stroke, performed DWI and perfusion-weighted MRI (PWI) on admission, at 5 days, 14 days, and 1 month after stroke, and assessed functional outcome at 3 months (Rankin Scale). Patient characteristics and DWI/PWI values were compared for patients with or without "still hyperintense" infarct areas on 1-month DWI.
RESULTS: Among 42 patients, 27 (64%) had "still hyperintense" infarct regions at 1 month, mostly in white matter. Patients with "still hyperintense" regions at 1 month had lower baseline apparent diffusion coefficient ratio (ADCr; mean+/-SD 0.76+/-0.12 versus 0.85+/-0.12; hyperintense versus isointense; P<0.05), prolonged reduction of ADCr (repeated-measures ANOVA; P<0.01), no difference in baseline perfusion but delayed normalization of mean transit time (P<0.05) and cerebral blood flow ratios (repeated measures ANOVA; P<0.05), initially more severe stroke, and worse 3-month outcome than patients whose lesions were isointense by 1 month.
CONCLUSIONS: The late DWI lesion hyperintensity emphasizes the heterogeneity in temporal evolution of stroke injury and suggests ongoing "ischemia." Lower baseline ADCr precedes delayed perfusion normalization, suggesting that worse cell swelling impedes reperfusion. Further study is required to determine underlying mechanisms and any potential for subacute intervention to improve recovery.

Entities:  

Mesh:

Year:  2006        PMID: 16645138     DOI: 10.1161/01.STR.0000221294.90068.c4

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  12 in total

Review 1.  Inflammatory cytokines in experimental and human stroke.

Authors:  Kate Lykke Lambertsen; Knut Biber; Bente Finsen
Journal:  J Cereb Blood Flow Metab       Date:  2012-06-27       Impact factor: 6.200

2.  Serial magnetic resonance images of a right middle cerebral artery infarction : persistent hyperintensity on diffusion-weighted MRI over 8 months.

Authors:  Seungnam Son; Dae Seob Choi; Nack-Cheon Choi; Byeong Hoon Lim
Journal:  J Korean Neurosurg Soc       Date:  2011-10-31

3.  Response to Letter Regarding Article, "Clinically Confirmed Stroke With Negative Diffusion-Weighted Imaging Magnetic Resonance Imaging: Longitudinal Study of Clinical Outcomes, Stroke Recurrence, and Systematic Review".

Authors:  Stephen D J Makin; Joanna M Wardlaw
Journal:  Stroke       Date:  2016-01-19       Impact factor: 7.914

4.  Plasma glial fibrillary acidic protein levels in children with sickle cell disease.

Authors:  William J Savage; Emily Barron-Casella; Zongming Fu; Pratima Dulloor; Lisa Williams; Barbara J Crain; Desiree A White; Jacky M Jennings; Jennifer E Van Eyk; Michael R Debaun; Allen Everett; James F Casella
Journal:  Am J Hematol       Date:  2011-05       Impact factor: 10.047

Review 5.  MR Perfusion in the Evaluation of Mechanical Thrombectomy Candidacy.

Authors:  Varsha Muddasani; Adam de Havenon; J Scott McNally; Hediyeh Baradaran; Matthew D Alexander
Journal:  Top Magn Reson Imaging       Date:  2021-08-01

6.  WebParc: a tool for analysis of the topography and volume of stroke from MRI.

Authors:  David N Kennedy; Christian Haselgrove; Nikos Makris; Donald M Goldin; Michael H Lev; David Caplan; Verne S Caviness
Journal:  Med Biol Eng Comput       Date:  2010-03       Impact factor: 2.602

Review 7.  Cell therapy for stroke: remaining issues to address before embarking on clinical trials.

Authors:  Cesar V Borlongan
Journal:  Stroke       Date:  2008-12-08       Impact factor: 7.914

Review 8.  Cell therapy for stroke: emphasis on optimizing safety and efficacy profile of endothelial progenitor cells.

Authors:  Yuji Kaneko; Naoki Tajiri; Kazutaka Shinozuka; Loren E Glover; Nathan L Weinbren; Lourdes Cortes; Cesar V Borlongan
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

9.  A Step-up Approach for Cell Therapy in Stroke: Translational Hurdles of Bone Marrow-Derived Stem Cells.

Authors:  Loren E Glover; Naoki Tajiri; Nathan L Weinbren; Hiroto Ishikawa; Kazutaka Shinozuka; Yuji Kaneko; D Martin Watterson; Cesar V Borlongan
Journal:  Transl Stroke Res       Date:  2011-11-18       Impact factor: 6.829

10.  The prognosis of allocentric and egocentric neglect: evidence from clinical scans.

Authors:  Magdalena Chechlacz; Pia Rotshtein; Katherine L Roberts; Wai-Ling Bickerton; Johnny K L Lau; Glyn W Humphreys
Journal:  PLoS One       Date:  2012-11-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.